中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

14 records (took 0.022 seconds)

    SYSTEMS AND METHODS FOR THE DETECTION OF INFECTIOUS DISEASES
    3.
    发明申请
    SYSTEMS AND METHODS FOR THE DETECTION OF INFECTIOUS DISEASES 审中-公开
    用于检测传染病的系统和方法

    公开(公告)号：WO2017139715A1

    公开(公告)日：2017-08-17

    申请号：PCT/US2017/017573

    申请日：2017-02-11

    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE ,  ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY

    Inventor： DRIEBE, Elizabeth ,  KEIM, Paul ,  ENGELTHALER, David ,  BOWERS, Jolene ,  NIETO, Nate

    IPC: G01N33/569 ,  G01N33/50 ,  C12Q1/04

    CPC classification number: C12Q1/6883 ,  C12Q1/689 ,  Y02A50/57

    Abstract: The present invention relates to method of detecting and characterizing one or more Borrelia species causing Lyme Disease or tick-borne relapsing fever within a sample from a subject, the method comprising: a) subjecting DNA and/or RNA from the sample to a PCR amplification reaction using primer pairs targeting at least one region of Borrelia 16S rRNA and at least one region of flaB , ospA, ospB , ospC , glpQ , 16S-23S intergenic spacer (IGS1), 5S-23S intergenic spacer (IGS2), bbk32 , dbpA , dbpB , and/or p66 ; and b) analyzing amplification products resulting from the PCR amplification reaction to detect the one or more Borrelia species.

    Abstract translation: 本发明涉及在来自受试者的样品内检测和表征引起莱姆病或蜱传回归热的一种或多种疏螺旋体属物种的方法，所述方法包括： a）使用靶向至少一个疏螺旋体16S rRNA区域和至少一个flaB区域的引物对将来自样品的DNA和/或RNA进行PCR扩增反应， ospA，ospB，ospC，glpQ，16S-23S基因间隔区（IGS1），5S-23S基因间隔区（IGS2） bbk32“，”dbpA“，”dbpB“和/或”p66“; 和b）分析PCR扩增反应产生的扩增产物以检测一种或多种疏螺旋体属物种。

    METHODS AND KITS FOR THE DETECTION OF SARS-COV-2
    5.
    发明申请
    METHODS AND KITS FOR THE DETECTION OF SARS-COV-2 审中-公开

    公开(公告)号：WO2021183902A1

    公开(公告)日：2021-09-16

    申请号：PCT/US2021/022132

    申请日：2021-03-12

    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

    Inventor： ENGELTHALER, David ,  BOWERS, Jolene ,  SCHUPP, James

    IPC: C12Q1/70

    Abstract: Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 42 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5' terminus is labeled with a fluorophore and the 3' terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

    METHODS AND KITS FOR THE DETECTION OF SARS-COV-2
    6.
    发明申请
    METHODS AND KITS FOR THE DETECTION OF SARS-COV-2 审中-公开

    公开(公告)号：WO2021183893A1

    公开(公告)日：2021-09-16

    申请号：PCT/US2021/022114

    申请日：2021-03-12

    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

    Inventor： ENGELTHALER, David ,  BOWERS, Jolene ,  SCHUPP, James

    IPC: C12Q1/6888 ,  C12N15/50 ,  C12Q1/6844 ,  C12Q1/686 ,  C12Q1/6869

    Abstract: Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 40 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5' terminus is labeled with a fluorophore and the 3' terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

    SYSTEMS AND METHODS FOR UNIVERSAL TAIL-BASED INDEXING STRATEGIES FOR AMPLICON SEQUENCING
    7.
    发明申请
    SYSTEMS AND METHODS FOR UNIVERSAL TAIL-BASED INDEXING STRATEGIES FOR AMPLICON SEQUENCING 审中-公开
    用于AMPLICON序列的通用基于尾段的指数策略的系统和方法

    公开(公告)号：WO2015070187A2

    公开(公告)日：2015-05-14

    申请号：PCT/US2014/064890

    申请日：2014-11-10

    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

    Inventor： SCHUPP, James M. ,  COLMAN, Rebecca ,  ENGELTHALER, David ,  GILLECE, John ,  HICKS, Nathan ,  KEIM, Paul S.

    IPC: A61B3/10

    CPC classification number: C12Q1/686 ,  C12Q1/6869 ,  C12Q1/6874 ,  C12Q2525/155 ,  C12Q2525/191 ,  C12Q2537/143

    Abstract: Some embodiments of the invention include a method of preparing a sample for sequencing that includes receiving a sample and amplifying at least one marker within the sample. In some embodiments, amplification of the first marker may include mixing the sample with a first oligonucleotide that comprises a first universal tail sequence and a second oligonucleotide that comprises a second universal tail sequence. In some aspects of the invention, the first universal tail sequence and the second universal tail sequence are different sequences.

    Abstract translation: 本发明的一些实施方案包括制备用于测序的样品的方法，其包括接收样品并扩增样品中的至少一个标记物。 在一些实施方案中，第一标记的扩增可以包括将样品与包含第一通用尾部序列的第一寡核苷酸和包含第二通用尾部序列的第二寡核苷酸混合。 在本发明的一些方面，第一通用尾部序列和第二通用尾部序列是不同的序列。

    METHODS AND KITS FOR THE DETECTION OF MERS-COV
    8.
    发明申请
    METHODS AND KITS FOR THE DETECTION OF MERS-COV 审中-公开

    公开(公告)号：WO2021183897A1

    公开(公告)日：2021-09-16

    申请号：PCT/US2021/022119

    申请日：2021-03-12

    Applicant: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

    Inventor： ENGELTHALER, David ,  BOWERS, Jolene ,  SCHUPP, James

    IPC: C12Q1/6888 ,  C12N15/50 ,  C12Q1/6844 ,  C12Q1/686 ,  C12Q1/6869

    Abstract: Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (MERS-CoV), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 40 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5' terminus is labeled with a fluorophore and the 3' terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.

Patent Agency Ranking